Vitamin K experts critical towards simplified message from Emaus' study
(Thomson Reuters ONE) -
23.April 2010, Lysaker - In a recently published study by Emaus et al. at the
University of Tromsø (Osteoporos. Int. 2009, Epub ahead of print), the effect of
vitamin K2 on bone loss in women in early menopause was measured. 334 healthy
women between 50 and 60 years old were divided into two groups, one group
received 360?g MK-7 capsule and the other group received placebo capsules. After
1 year of study, the treatment group demonstrated a positive change in the
biochemical markers related to improved bone health. No significant difference
was found in bone loss or bone mass between the two groups. Emaus et al
therefore draw the conclusion that vitamin K2 has no effect on bone loss in
women between 50-60 years old.
It is a fact that changes in biochemical markers appear faster than changes in
bone mass. NattoPharma therefore believes that if the study had stretched over
longer time, one would most likely have seen a positive result also in bone
mass.
NattoPharma sees that some Norwegian media has recently referred to the Emaus
study and concluded that there is no association between vitamin K2 and bone
health. NattoPharma believes this creates unnecessary uncertainty among
consumers. Experts in vitamin K research recommend strongly, based on worldwide
research results over the past decade, all people to take vitamin K2 for general
bone health. Based on all relevant studies and thorough evaluation by experts in
this field, the authorities in the EU has also concluded that there is a
positive association between intake of vitamin K2 and good bone health.
NattoPharma has received a comment regarding the results of Emaus et al from Dr.
Cees Vermeer at VitaK BV, Maastricht University, a respected and experienced
vitamin K researcher at the world's leading vitamin K research center: "In a new
review of Iwamoto et al. (2009) the minimum criteria for studies of vitamin K
and bone health are defined (Iwamoto, J. et.al., 2009. High-dose vitamin K
supplementation reducer Fracture incidences in postmenopausal women: a review of
the literature. Nutr. Res. 29: 221-8).
These criteria are:
Many studies have been published that do not meet these criteria, and one of
them is the recently published study by Emaus et al (2009). Studies in which
changes in biomarkers are used as endpoints may be 3-6 months, while those using
bone mineral density (BMD) as a clinical endpoint should be longer than 2 years.
I expect that an extension of the study by another 2 years would have shown a
positive effect of vitamin K2 in bone density and bone strength. "
Dr. Leon Schurgers, VP R&D in NattoPharma, explains that this is why NattoPharma
has chosen a 3-year randomized clinical trial to demonstrate the effect of
MenaQ7, NattoPharma's vitamin K2. Dr. Schurgers elaborates further: "All vitamin
K intervention trials lasting less than 2 years have unfortunately contributed
to confusion regarding the effect of vitamin K supplements. The study of Emaus
et al is no exception."
For more information:
CEO Morten Sundstø
Phone: +47 950 61860
[HUG#1407355]
Vitamin K experts critical towards simplified message from Emaus? study : http://hugin.info/137386/R/1407355/360648.pdf
Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2010 - 12:56 Uhr
Sprache: Deutsch
News-ID 19589
Anzahl Zeichen: 0
contact information:
Town:
LYSAKER
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 311 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vitamin K experts critical towards simplified message from Emaus' study"
steht unter der journalistisch-redaktionellen Verantwortung von
NattoPharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
